LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2021
LifeVantage Corporation (Nasdaq: LFVN) announced its fourth quarter and full year financial results for fiscal 2021, reporting revenue of $220.2 million, a 5.5% decline from the previous year. The fourth quarter revenue reached $54.8 million, down 7.7% year-over-year but up 6.2% sequentially. Adjusted EPS for Q4 was $0.31, up 10.7%. The company repurchased 1.2 million shares for $11.9 million and has a solid balance sheet with $23.2 million in cash and no debt. Guidance for fiscal 2022 forecasts revenue between $225 million and $235 million.
- Adjusted EPS increased 10.7% year-over-year to $0.31.
- Repurchased 1.2 million shares, totaling $11.9 million.
- Guidance for fiscal 2022 expects revenue between $225 million and $235 million.
- Fourth quarter revenue decreased 7.7% year-over-year.
- Total active accounts decreased 5.0% compared to the prior period.
- Fiscal 2021 revenue declined 5.5% to $220.2 million.
Revenue of
Fourth Quarter Adjusted EPS Increased
SALT LAKE CITY, Aug. 19, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its fourth quarter and full fiscal year ended June 30, 2021.
Fourth Quarter Fiscal 2021 Summary*:
- Revenue of
$54.8 million , a decrease of7.7% from the prior year period and an increase of6.2% sequentially; - Total active accounts decreased
5.0% compared to the prior period while increasing1.2% sequentially to 170,000. The year over year decline includes a decline in distributors of13.7% , partially offset by an increase of0.9% in customers. Compared to the third quarter of fiscal 2021, the number of distributors was flat and customers grew by1.9% ; - Earnings per diluted share were
$0.35 , up34.6% over the prior year period and up191.7% sequentially; - Adjusted earnings per diluted share were
$0.31 , up10.7% compared to$0.28 in the prior year period and up55.0% sequentially; and - Adjusted EBITDA decreased
19.3% to$6.6 million compared to the prior period and increased37.9% sequentially.
* All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2021 to the fourth quarter of fiscal 2020, unless otherwise noted.
Fiscal Year 2021 Summary**:
- Revenue decreased
5.5% to$220.2 million ; - Revenue in the Americas decreased
7.0% and revenue in Asia/Pacific & Europe decreased1.6% ; - Earnings per diluted share were
$0.90 , compared to$0.79 in fiscal 2020; - Adjusted earnings per diluted share were
$1.00 , compared to$0.86 in fiscal 2020; - Adjusted EBITDA increased
3.7% to$24.8 million ; - Repurchased 1.2 million, or
$11.9 million , of common shares; and - Strong balance sheet with
$23.2 million of cash and no debt.
**All growth rates compare fiscal 2021 to fiscal 2020.
“Fourth quarter revenues results were in line with our expectations and earnings were slightly ahead as we continued to focus on our core strategies for driving long-term growth and operational improvement. Adjusted earnings per share increased
Fourth Quarter Fiscal 2020 Results
For the fourth fiscal quarter ended June 30, 2021, the Company reported revenue of
Gross profit for the fourth quarter of fiscal 2021 was
Commissions and incentives expense for the fourth quarter of fiscal 2021 was
Selling, general and administrative expense (SG&A) for the fourth quarter of fiscal 2021 was
Operating income for the fourth quarter of fiscal 2021 was
Net income for the fourth quarter of fiscal 2021 was
Adjusted EBITDA decreased
Fiscal 2021 Full Year Results
For the fiscal year ended June 30, 2021, the Company reported net revenue of
Gross profit during fiscal 2021 was
Commissions and incentives expense for fiscal 2021 was
SG&A expense for fiscal 2021 was
Operating income for fiscal 2021 was
Net income for fiscal 2021 was
Adjusted EBITDA increased
Balance Sheet & Liquidity
The Company generated
Fiscal Year 2022 Guidance
The Company expects to generate revenue in the range of
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 705-6003 from the U.S. International callers can dial (201) 493-6725. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, August 26, 2021, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13721246, or (412) 317-6671 from international locations, and entering confirmation code 13721246.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at http://investor.lifevantage.com/events-and-presentations or directly at http://public.viavid.com/index.php?id=145578.The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company’s line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, and Daily Wellness dietary supplements, TrueScience® is the Company's line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio® its nootropic energy drink mixes, and PhysIQ™, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected financial performance. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||
CONSOLIDATED BALANCE SHEETS | |||||||
As of | |||||||
(In thousands, except per share data) | June 30, 2021 | June 30, 2020 | |||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 23,174 | $ | 22,138 | |||
Accounts receivable | 2,925 | 2,610 | |||||
Income tax receivable | 1,038 | — | |||||
Inventory, net | 16,145 | 13,888 | |||||
Prepaid expenses and other | 4,772 | 5,232 | |||||
Total current assets | 48,054 | 43,868 | |||||
Property and equipment, net | 11,123 | 7,170 | |||||
Right-of-use assets | 13,700 | 956 | |||||
Intangible assets, net | 719 | 851 | |||||
Deferred income tax asset | 1,208 | 2,164 | |||||
Equity securities | 2,205 | 2,205 | |||||
Other long-term assets | 1,723 | 1,663 | |||||
TOTAL ASSETS | $ | 78,732 | $ | 58,877 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities | |||||||
Accounts payable | $ | 6,744 | $ | 3,521 | |||
Commissions payable | 8,138 | 9,219 | |||||
Income tax payable | 830 | 784 | |||||
Lease liabilities | 2,151 | 1,184 | |||||
Other accrued expenses | 7,336 | 10,311 | |||||
Current portion of long-term debt, net | — | — | |||||
Total current liabilities | 25,199 | 25,019 | |||||
Long-term lease liabilities | 16,032 | — | |||||
Other long-term liabilities | 694 | 604 | |||||
Total liabilities | 41,925 | 25,623 | |||||
Commitments and contingencies | |||||||
Stockholders' equity | |||||||
Preferred stock — par value | — | — | |||||
Common stock — par value | 1 | 1 | |||||
Additional paid-in capital | 129,048 | 126,416 | |||||
Accumulated deficit | (92,346 | ) | (93,307 | ) | |||
Accumulated other comprehensive income | 104 | 144 | |||||
Total stockholders’ equity | 36,807 | 33,254 | |||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 78,732 | $ | 58,877 | |||
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
For the Three Months Ended June 30, (unaudited) | Fiscal Year Ended June 30, | ||||||||||||||
(In thousands, except per share data) | 2021 | 2020 | 2021 | 2020 | |||||||||||
Revenue, net | $ | 54,777 | $ | 59,368 | $ | 220,181 | $ | 232,915 | |||||||
Cost of sales | 9,782 | 9,449 | 38,187 | 37,964 | |||||||||||
Gross profit | 44,995 | 49,919 | 181,994 | 194,951 | |||||||||||
Operating expenses: | |||||||||||||||
Commissions and incentives | 25,603 | 28,894 | 103,541 | 111,571 | |||||||||||
Selling, general and administrative | 12,811 | 14,816 | 60,838 | 67,914 | |||||||||||
Total operating expenses | 38,414 | 43,710 | 164,379 | 179,485 | |||||||||||
Operating income | 6,581 | 6,209 | 17,615 | 15,466 | |||||||||||
Other expense: | |||||||||||||||
Interest expense | — | (1 | ) | (17 | ) | (120 | ) | ||||||||
Other expense, net | (103 | ) | (120 | ) | (366 | ) | (685 | ) | |||||||
Total other expense | (103 | ) | (121 | ) | (383 | ) | (805 | ) | |||||||
Income before income taxes | 6,478 | 6,088 | 17,232 | 14,661 | |||||||||||
Income tax expense | (1,571 | ) | (2,264 | ) | (4,338 | ) | (3,112 | ) | |||||||
Net income | $ | 4,907 | $ | 3,824 | $ | 12,894 | $ | 11,549 | |||||||
Net income per share: | |||||||||||||||
Basic | $ | 0.36 | $ | 0.27 | $ | 0.92 | $ | 0.82 | |||||||
Diluted | $ | 0.35 | $ | 0.26 | $ | 0.90 | $ | 0.79 | |||||||
Weighted-average shares outstanding: | |||||||||||||||
Basic | 13,754 | 14,258 | 14,070 | 14,105 | |||||||||||
Diluted | 13,879 | 14,703 | 14,268 | 14,599 |
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | ||||||||||||||||||||||||||||
Revenue by Region | ||||||||||||||||||||||||||||
Three Months Ended June 30, (unaudited) | Fiscal Year Ended June 30, | |||||||||||||||||||||||||||
(In thousands) | 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||||||
Americas | $ | 37,677 | 69 | % | $ | 41,690 | 70 | % | $ | 154,655 | 70 | % | $ | 166,336 | 71 | % | ||||||||||||
Asia/Pacific & Europe | 17,100 | 31 | % | 17,678 | 30 | % | 65,526 | 30 | % | 66,579 | 29 | % | ||||||||||||||||
Total | $ | 54,777 | 100 | % | $ | 59,368 | 100 | % | $ | 220,181 | 100 | % | $ | 232,915 | 100 | % | ||||||||||||
Active Accounts (unaudited) | ||||||||||||||||||||||||||||
As of June 30, | ||||||||||||||||||||||||||||
2021 | 2020 | Change from Prior Year | Percent Change | |||||||||||||||||||||||||
Active Independent Distributors(1) | ||||||||||||||||||||||||||||
Americas | 41,000 | 65 | % | 49,000 | 67 | % | (8,000 | ) | (16.3 | ) | % | |||||||||||||||||
Asia/Pacific & Europe | 22,000 | 35 | % | 24,000 | 33 | % | (2,000 | ) | (8.3 | ) | % | |||||||||||||||||
Total Active Independent Distributors | 63,000 | 100 | % | 73,000 | 100 | % | (10,000 | ) | (13.7 | ) | % | |||||||||||||||||
Active Customers(2) | ||||||||||||||||||||||||||||
Americas | 78,000 | 73 | % | 83,000 | 78 | % | (5,000 | ) | (6.0 | ) | % | |||||||||||||||||
Asia/Pacific & Europe | 29,000 | 27 | % | 23,000 | 22 | % | 6,000 | 26.1 | % | |||||||||||||||||||
Total Active Customers | 107,000 | 100 | % | 106,000 | 100 | % | 1,000 | 0.9 | % | |||||||||||||||||||
Active Accounts(3) | ||||||||||||||||||||||||||||
Americas | 119,000 | 70 | % | 132,000 | 74 | % | (13,000 | ) | (9.8 | ) | % | |||||||||||||||||
Asia/Pacific & Europe | 51,000 | 30 | % | 47,000 | 26 | % | 4,000 | 8.5 | % | |||||||||||||||||||
Total Active Accounts | 170,000 | 100 | % | 179,000 | 100 | % | (9,000 | ) | (5.0 | ) | % | |||||||||||||||||
(1) Active Independent Distributors have purchased product in the prior three months for retail or personal consumption. | ||||||||||||||||||||||||||||
(2) Active Customers have purchased product in the prior three months for personal consumption only. | ||||||||||||||||||||||||||||
(3) Total Active Accounts is the sum of Active Independent Distributors and Active Customers. |
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA: | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended June 30, | Fiscal Year Ended June 30, | ||||||||||||||
(In thousands) | 2021 | 2020 | 2021 | 2020 | |||||||||||
GAAP Net income | $ | 4,907 | $ | 3,824 | $ | 12,894 | $ | 11,549 | |||||||
Interest expense | — | 1 | 17 | 120 | |||||||||||
Provision for income taxes | 1,571 | 2,264 | 4,338 | 3,112 | |||||||||||
Depreciation and amortization(1) | 817 | 824 | 3,460 | 2,777 | |||||||||||
Non-GAAP EBITDA: | 7,295 | 6,913 | 20,709 | 17,558 | |||||||||||
Adjustments: | |||||||||||||||
Stock compensation expense | (79 | ) | 838 | 2,036 | 4,919 | ||||||||||
Other expense, net | 103 | 120 | 366 | 685 | |||||||||||
Other adjustments(2) | (700 | ) | 334 | 1,736 | 806 | ||||||||||
Total adjustments | (676 | ) | 1,292 | 4,138 | 6,410 | ||||||||||
Non-GAAP Adjusted EBITDA | $ | 6,619 | $ | 8,205 | $ | 24,847 | $ | 23,968 | |||||||
(1) Includes | |||||||||||||||
(2) Other adjustments breakout: | |||||||||||||||
Lease abandonment | $ | — | $ | — | $ | 495 | $ | — | |||||||
Class-action lawsuit expenses, net of recoveries | $ | (1,002 | ) | $ | 334 | $ | (144 | ) | $ | 703 | |||||
Executive team severance expenses, net | 160 | — | 851 | — | |||||||||||
Executive team recruiting and transition expenses | 142 | — | 534 | — | |||||||||||
Other nonrecurring legal and accounting expenses | — | — | — | 103 | |||||||||||
Insurance reimbursement | — | — | — | — | |||||||||||
Change in estimate of accrued import liabilities | — | — | — | — | |||||||||||
Total adjustments | $ | (700 | ) | $ | 334 | $ | 1,736 | $ | 806 |
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS: | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended June 30, | Fiscal Year Ended June 30, | ||||||||||||||
(In thousands) | 2021 | 2020 | 2021 | 2020 | |||||||||||
GAAP Net income | $ | 4,907 | $ | 3,824 | $ | 12,894 | $ | 11,549 | |||||||
Adjustments: | |||||||||||||||
Executive team severance expenses, net(1) | 83 | — | 269 | — | |||||||||||
Executive team recruiting and transition expenses | 142 | — | 534 | — | |||||||||||
Lease abandonment(2) | — | — | 830 | — | |||||||||||
Class-action lawsuit expenses, net of recoveries | (1,002 | ) | 334 | (144 | ) | 703 | |||||||||
Other nonrecurring legal and accounting expenses | — | — | — | 103 | |||||||||||
Accelerated depreciation related to change in lease term | — | 152 | 101 | 456 | |||||||||||
Tax impact of adjustments | 188 | (181 | ) | (192 | ) | (323 | ) | ||||||||
Total adjustments, net of tax | (589 | ) | 305 | 1,398 | 939 | ||||||||||
Non-GAAP Net Income | $ | 4,318 | $ | 4,129 | $ | 14,292 | $ | 12,488 | |||||||
Three Months Ended June 30, | Fiscal Year Ended June 30, | ||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||
Diluted earnings per share, as reported | $ | 0.35 | $ | 0.26 | $ | 0.90 | $ | 0.79 | |||||||
Total adjustments, net of tax | (0.04 | ) | 0.02 | 0.10 | 0.06 | ||||||||||
Diluted earnings per share, as adjusted(3) | $ | 0.31 | $ | 0.28 | $ | 1.00 | $ | 0.86 | |||||||
(1) Net of | |||||||||||||||
(2) Includes remaining lease rent expense of | |||||||||||||||
(3) May not add due to rounding. |
FAQ
What was LifeVantage's revenue in the fourth quarter of fiscal 2021?
How did LifeVantage's adjusted EPS perform in Q4 of fiscal 2021?
What is LifeVantage's revenue guidance for fiscal year 2022?
What was the total revenue for LifeVantage in fiscal year 2021?